New York Dangerous Drug Lawyer

In New York, personal injury claims — including those arising from dangerous drugs — are subject to a **three-year statute of limitations** (CPLR § 214). The clock generally begins running from the date of injury.

**The discovery rule in New York is limited.** Unlike some states, New York does not broadly apply a discovery rule in standard personal injury cases. The injury date is generally when the harm occurred, not when you learned it was caused by the drug.

However, **CPLR § 214-c** provides a critical exception for claims arising from **exposure to substances** — including toxic or harmful drugs. Under this provision, the three-year period begins from the **date the injury was discovered or should reasonably have been discovered**, not the date of exposure. This can be extremely significant for drug cases where injury (such as cancer or organ damage) develops years after use.

For wrongful death claims arising from a drug injury, New York's two-year statute of limitations applies (EPTL § 5-4.1), running from the date of death.

New York follows standard product liability doctrine, recognizing three theories of defect:

**Manufacturing defect:** The specific product you received was produced improperly and deviated from the intended design. In drug cases, this often involves contamination (NDMA, sterility failures, mislabeling).

**Design defect:** The drug's formulation itself was unreasonably dangerous. New York uses a risk-utility balancing test: the product is defective if the risks outweigh its utility and a safer alternative design was feasible.

**Failure to warn:** The drug manufacturer failed to adequately warn prescribing physicians (or in some cases, patients) of known risks. New York recognizes the learned intermediary doctrine — drug companies generally satisfy their duty to warn through adequate labeling to prescribers, not patients directly. However, this doctrine does not apply when the company engaged in direct-to-consumer advertising.

Many major drug injury cases are litigated in federal Multidistrict Litigation (MDL) proceedings, which consolidate cases from across the country before a single judge. New York plaintiffs with individual claims against, for example, GLP-1 drug manufacturers, Zantac distributors, or NEC baby formula producers may be part of existing MDLs.

In addition, New York State Courts in New York County (Manhattan) have created coordinated proceedings for mass tort claims, similar to MDL structure. The New York Commercial Division and complex litigation courts have dedicated judges for pharmaceutical mass torts.

Being represented by counsel familiar with both the federal MDL system and the New York state coordinated proceeding options is important — strategy differs meaningfully between the two venues.

New York courts apply the same causation framework as most states: the plaintiff must establish general causation (the drug is capable of causing this type of injury) and specific causation (the drug caused this plaintiff's specific injury).

Both typically require expert testimony. Epidemiological evidence is generally required for general causation — studies showing a statistically significant association between the drug and the injury type. For specific causation, a treating physician or expert can testify to a differential diagnosis ruling out other causes.

New York's Frye standard (not Daubert) governs expert testimony in state court. Under Frye, expert opinions must be based on methods "generally accepted" in the relevant scientific community. This is a meaningful distinction from federal court, and expert strategy should account for it.

New York does not cap compensatory damages in personal injury cases, including those arising from dangerous drugs. Recoverable damages include:

— **Past and future medical expenses** — including hospitalizations, surgeries, ongoing treatment, and anticipated future care — **Past and future lost wages** — including diminished earning capacity — **Pain and suffering** — physical pain and emotional distress, past and future — **Loss of enjoyment of life** — the impact of the injury on daily activities and quality of life — **Out-of-pocket expenses** — transportation, home care, adaptive equipment

**Punitive damages** are available in New York where the defendant's conduct was reckless or showed a conscious disregard for the plaintiff's rights. In drug cases, this applies when companies concealed safety data, delayed recalls, or engaged in fraudulent FDA submissions. Punitive damages are not available in all drug cases — the evidence must support the heightened standard.

For wrongful death, damages include medical and funeral expenses, lost support and services, and in some circumstances, pre-death conscious pain and suffering.

When we assess a New York dangerous drug case, we apply the following framework:

1. **Timeline analysis:** When did you use the drug? When did the injury manifest? We assess whether the claim is time-barred under CPLR § 214 or § 214-c, and whether any tolling doctrines apply.

2. **MDL status check:** Is the drug the subject of existing federal or state mass tort litigation? If so, where is the litigation, and how does that affect your individual filing options?

3. **Causation evaluation:** Is there scientific or epidemiological evidence connecting this drug to your injury type? We review medical literature and consult with relevant experts.

4. **Damages assessment:** We evaluate medical records, employment records, and other documentation to fully scope your damages.

5. **Liability theory:** We determine which theory of defect — design, manufacturing, or warning — applies to your case and how it can be proven.

New York law provides meaningful protections for drug injury victims. If you believe you were harmed by a dangerous drug and are located in New York, contact us for a confidential case evaluation.